Memphasys Ltd (ASX:MEM)'s Alison Coutts gives the business case for the company's biological separation technology and its vision for 2022. The ASX-lister aims to establish its flagship Felix™ System — the first automated, non-DNA damaging lab instrument for sperm separation — as the gold standard method in human IVF clinics for preparing sperm from semen samples.
Memphasys outlines vision for biological separation tech in 2022
